跳至主要内容
临床试验/NCT00171613
NCT00171613已完成4 期

A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

Novartis0 个研究点目标入组 32 人开始时间: 2005年2月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
32
主要终点
Change from baseline in BMI

研究概览

简要总结

The extension protocol is designed to allow those patients randomized to placebo in the core portion of the protocol to receive a 6 month treatment of open label octreotide and allow those patients randomized to octreotide who appeared to benefit from treatment, to continue to receive octreotide.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • - Patient must provide written informed consent

排除标准

  • Any patient that experienced unresolved safety complications at any time during the original protocol CSMS995B2403
  • Patients with a history of gallstones or any patient developing gallstones during the course of the core protocol
  • Patients for whom there are safety or tolerability concerns for continuing Octreotide Depot
  • Any patient requiring additional treatment for their original cranial insult related to cranial trauma, or to tumor recurrence or its treatment Refer to the original protocol for details of inclusion & exclusion criteria. Any patient granted a waiver to participate in the core protocol will be allowed to continue to participate in the extension protocol.
  • Other protocol-defined inclusion / exclusion criteria may apply.

结局指标

主要结局

Change from baseline in BMI

次要结局

  • Change from baseline in weight, leptin, insulin AUC, C-peptide AUC, amylin AUC, glucose AUC, dietary intake, physical activity, waist-to-hip ratio, visceral and subcutaneous abdominal fat

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

相似试验